{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:21:21Z","timestamp":1776259281169,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1245\/s10434-026-19082-6","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T17:02:07Z","timestamp":1769101327000},"page":"4463-4471","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the Impact of a Surgeon-Led Ductal Carcinoma in Situ Program on Endocrine Therapy Uptake"],"prefix":"10.1245","volume":"33","author":[{"given":"Monika K.","family":"Masanam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Kantor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Pappas Brunco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda C.","family":"Faust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lila","family":"Tappan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria E.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline G.","family":"Dudman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline C.","family":"Block","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany L.","family":"Bychkovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer R.","family":"Bellon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Mittendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tari A.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"19082_CR1","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.ajpath.2018.07.031","volume":"189","author":"S Sanati","year":"2019","unstructured":"Sanati S. Morphologic and molecular features of breast ductal carcinoma in situ. Am J Pathol. 2019;189:946\u201355. https:\/\/doi.org\/10.1016\/j.ajpath.2018.07.031.","journal-title":"Am J Pathol."},{"key":"19082_CR2","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/s41379-019-0204-1","volume":"32","author":"WM Hanna","year":"2019","unstructured":"Hanna WM, Parra-Herran C, Lu FI, et al. Ductal carcinoma in situ of the breast: an update for the pathologist in the era of individualized risk assessment and tailored therapies. Mod Pathol. 2019;32:896\u2013915. https:\/\/doi.org\/10.1038\/s41379-019-0204-1.","journal-title":"Mod Pathol."},{"key":"19082_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin."},{"key":"19082_CR4","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.jamcollsurg.2019.01.018","volume":"228","author":"TO Oseni","year":"2019","unstructured":"Oseni TO, Zhang B, Coopey SB, et al. Twenty-five year trends in the incidence of ductal carcinoma in situ in US women. J Am Coll Surg. 2019;228:932\u20139. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2019.01.018.","journal-title":"J Am Coll Surg."},{"key":"19082_CR5","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1016\/S0140-6736(24)00425-2","volume":"403","author":"S Delaloge","year":"2024","unstructured":"Delaloge S, Khan SA, Wesseling J, Whelan T. Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment. Lancet. 2024;403:2734\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(24)00425-2.","journal-title":"Lancet."},{"key":"19082_CR6","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.1245\/s10434-011-1748-6","volume":"18","author":"J Fong","year":"2011","unstructured":"Fong J, Kurniawan ED, Rose AK, et al. Outcomes of screening-detected ductal carcinoma in situ treated with wide excision alone. Ann Surg Oncol. 2011;18:3778\u201384. https:\/\/doi.org\/10.1245\/s10434-011-1748-6.","journal-title":"Ann Surg Oncol."},{"issue":"9","key":"19082_CR7","doi-asserted-by":"publisher","first-page":"znae198","DOI":"10.1093\/bjs\/znae198","volume":"111","author":"SM Wang","year":"2024","unstructured":"Wang SM, Li Y, Nash A, et al. Disease-specific survival outcomes for patients after locoregional treatment for ductal carcinoma in situ: observational cohort study. Br J Surg. 2024;111(9):znae198. https:\/\/doi.org\/10.1093\/bjs\/znae198.","journal-title":"Br J Surg."},{"key":"19082_CR8","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1186\/s12885-015-1904-7","volume":"15","author":"KE Stuart","year":"2015","unstructured":"Stuart KE, Houssami N, Taylor R, Hayen A, Boyages J. Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis. BMC Cancer. 2015;15:890. https:\/\/doi.org\/10.1186\/s12885-015-1904-7.","journal-title":"BMC Cancer."},{"key":"19082_CR9","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/S0140-6736(99)05036-9","volume":"353","author":"B Fisher","year":"1999","unstructured":"Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353:1993\u20132000. https:\/\/doi.org\/10.1016\/S0140-6736(99)05036-9.","journal-title":"Lancet."},{"key":"19082_CR10","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S0140-6736(15)01129-0","volume":"387","author":"JF Forbes","year":"2016","unstructured":"Forbes JF, Sestak I, Howell A, et al. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet. 2016;387:866\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(15)01129-0.","journal-title":"Lancet."},{"key":"19082_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1470-2045(10)70266-7","volume":"12","author":"J Cuzick","year":"2011","unstructured":"Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK\/ANZ DCIS trial. Lancet Oncol. 2011;12:21\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(10)70266-7.","journal-title":"Lancet Oncol."},{"key":"19082_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1634\/theoncologist.2015-0310","volume":"21","author":"HB Nichols","year":"2016","unstructured":"Nichols HB, Bowles EJ, Islam J, et al. Tamoxifen initiation after ductal carcinoma in situ. Oncologist. 2016;21:134\u201340. https:\/\/doi.org\/10.1634\/theoncologist.2015-0310.","journal-title":"Oncologist."},{"key":"19082_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10549-022-06577-5","volume":"193","author":"B Bychkovsky","year":"2022","unstructured":"Bychkovsky B, Laws A, Katlin F, et al. Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen. Breast Cancer Res Treat. 2022;193:417\u201327. https:\/\/doi.org\/10.1007\/s10549-022-06577-5.","journal-title":"Breast Cancer Res Treat."},{"key":"19082_CR14","doi-asserted-by":"publisher","first-page":"6091709","DOI":"10.1155\/2017\/6091709","volume":"2017","author":"C Anderson","year":"2017","unstructured":"Anderson C, Winn AN, Dusetzina SB, Nichols HB. Endocrine therapy initiation among older women with ductal carcinoma in situ. J Cancer Epidemiol. 2017;2017:6091709. https:\/\/doi.org\/10.1155\/2017\/6091709.","journal-title":"J Cancer Epidemiol."},{"key":"19082_CR15","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1200\/JCO.2010.33.0258","volume":"29","author":"AN Freedman","year":"2011","unstructured":"Freedman AN, Yu B, Gail MH, et al. Benefit\/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol. 2011;29:2327\u201333. https:\/\/doi.org\/10.1200\/JCO.2010.33.0258.","journal-title":"J Clin Oncol."},{"key":"19082_CR16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3332\/ecancer.2015.595","volume":"9","author":"A DeCensi","year":"2015","unstructured":"DeCensi A, Thorat MA, Bonanni B, Smith SG, Cuzick J. Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake. Ecancermedicalscience. 2015;9:595. https:\/\/doi.org\/10.3332\/ecancer.2015.595.","journal-title":"Ecancermedicalscience."},{"key":"19082_CR17","doi-asserted-by":"publisher","first-page":"e414","DOI":"10.3399\/bjgp17X689377","volume":"67","author":"SG Smith","year":"2017","unstructured":"Smith SG, Foy R, McGowan JA, et al. Prescribing tamoxifen in primary care for the prevention of breast cancer: a national online survey of GPs\u2019 attitudes. Br J Gen Pract. 2017;67:e414\u201327. https:\/\/doi.org\/10.3399\/bjgp17X689377.","journal-title":"Br J Gen Pract."},{"key":"19082_CR18","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1245\/s10434-024-16857-7","volume":"32","author":"K Paschalis","year":"2025","unstructured":"Paschalis K, Marin C, Miller K, et al. Patients with DCIS seen at a specialized high-risk breast clinic run by surgical advanced practice providers have high rates of preventive medication uptake. Ann Surg Oncol. 2025;32:2526\u201333. https:\/\/doi.org\/10.1245\/s10434-024-16857-7.","journal-title":"Ann Surg Oncol."},{"key":"19082_CR19","doi-asserted-by":"publisher","first-page":"5962","DOI":"10.1245\/s10434-023-14162-3","volume":"30","author":"S Cai","year":"2023","unstructured":"Cai S. The breast surgeon\u2019s role in risk-reducing medication uptake. Ann Surg Oncol. 2023;30:5962\u20134. https:\/\/doi.org\/10.1245\/s10434-023-14162-3.","journal-title":"Ann Surg Oncol."},{"key":"19082_CR20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/annonc\/mdv590","volume":"27","author":"SG Smith","year":"2016","unstructured":"Smith SG, Sestak I, Forster A, et al. Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Ann Oncol. 2016;27:575\u201390. https:\/\/doi.org\/10.1093\/annonc\/mdv590.","journal-title":"Ann Oncol."},{"key":"19082_CR21","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1200\/JCO.22.02900","volume":"41","author":"M Lazzeroni","year":"2023","unstructured":"Lazzeroni M, Puntoni M, Guerrieri-Gonzaga A, et al. Randomized placebo-controlled trial of low-dose tamoxifen to prevent recurrence in breast noninvasive neoplasia: a 10-year follow-up of TAM-01 study. J Clin Oncol. 2023;41:3116\u201321. https:\/\/doi.org\/10.1200\/JCO.22.02900.","journal-title":"J Clin Oncol."},{"key":"19082_CR22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.clbc.2024.12.020","volume":"25","author":"R Patel","year":"2025","unstructured":"Patel R, Jin C, Jaber D, et al. Low-dose tamoxifen for breast cancer prevention: a real-world experience. Clin Breast Cancer. 2025;25:283\u201390. https:\/\/doi.org\/10.1016\/j.clbc.2024.12.020.","journal-title":"Clin Breast Cancer."},{"key":"19082_CR23","doi-asserted-by":"publisher","first-page":"8866","DOI":"10.1245\/s10434-024-16025-x","volume":"31","author":"BM Connors","year":"2024","unstructured":"Connors BM, Thompson JL, Miodonski MA, et al. Has the option of low-dose tamoxifen impacted chemoprevention uptake among women with breast intra-epithelial neoplasia? Ann Surg Oncol. 2024;31:8866\u201372. https:\/\/doi.org\/10.1245\/s10434-024-16025-x.","journal-title":"Ann Surg Oncol."},{"key":"19082_CR24","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1158\/1078-0432.CCR-20-4213","volume":"27","author":"A DeCensi","year":"2021","unstructured":"DeCensi A, Puntoni M, Johansson H, et al. Effect modifiers of low-dose tamoxifen in a randomized trial in breast noninvasive disease. Clin Cancer Res. 2021;27:3576\u201383. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4213.","journal-title":"Clin Cancer Res."},{"key":"19082_CR25","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/cncr.30425","volume":"123","author":"H Zhao","year":"2017","unstructured":"Zhao H, Hei N, Wu Y, et al. Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ. Cancer. 2017;123:940\u20137. https:\/\/doi.org\/10.1002\/cncr.30425.","journal-title":"Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19082-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19082-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19082-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:27:19Z","timestamp":1776256039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19082-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["19082"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19082-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Elizabeth A. Mittendorf reports compensated service on scientific advisory boards for AstraZeneca, BioNTech, Merck, and Moderna; uncompensated service on steering committees for Bristol Myers Squibb and Roche\/Genentech; speaker honoraria and travel support from Merck Sharp & Dohme; and institutional research support from Roche\/Genentech (via SU2C grant) and Gilead. She also resports research funding from Susan Komen for the Cure, for which she serves as a Scientific Advisor, and uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors. Tari A. King reports speaker honoraria for Exact Sciences, compensated service on the FES Steering Committee for GE Healthcare, compensated service for advisory board role for Veracyte and Ataraxis AI, and compensated service as faculty for PrecisCa cancer information service. The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}